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Abstract Cyclosporin (Cs-A) is an effective treatment
for difficult cases of nephrotic syndrome (NS), but its
use can be complicated by renal toxicity and a high inci-
dence of relapses after withdrawal. We reviewed the
charts of 10 Cs-A-dependent patients and 4 patients with
steroid-dependent nephrotic syndrome (SDNS) not pre-
viously treated with Cs-A therapy. All patients had per-
sistent NS, even after prior treatment with oral cyclo-
phosphamide. Of 10 patients treated with Cs-A, 4 had
surveillance renal biopsies consistent with Cs-A toxicity,
and 8 of 10 had interstitial fibrosis prior to mycopheno-
late mofetil (MMF). Patients were treated with MMF, at
1,200 mg/m2 per day, in an attempt to allow weaning of
Cs-A and/or steroid therapy, and reduce the frequency of
relapses. Overall, a significant decrease in frequency of
relapses was noted after initiation of MMF therapy. In
addition, 5 patients were weaned off Cs-A by 1–2 years
of follow-up. One patient was weaned off Cs-A and
MMF, and remained in complete remission. However,
the subgroup of patients with frequently relapsing SDNS
not treated with Cs-A appeared to have a reduction in the
number of relapses while on MMF that did not reach 
statistical significance. Two patients with intractable 
steroid-resistant NS continued to relapse repeatedly on
MMF and Cs-A therapy. We conclude that in this small,
single-center, uncontrolled experience, MMF therapy in
patients with Cs-A-dependent NS appears to be effective
in reducing Cs-A exposure. In addition, MMF appears to
significantly decrease the frequency of relapses in this
patient population. Further controlled studies are war-
ranted to better define the potential efficacy and side 
effects of long-term MMF therapy in this setting.
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Introduction
Patients with steroid-resistant nephrotic syndrome
(SRNS) and frequently relapsing steroid-dependent
nephrotic syndrome (FR-SDNS) often experience signif-
icant morbidity due to complications associated with dis-
ease, such as acute renal failure, infection, thrombosis,
and progression to end-stage renal disease. There is also
a significant risk of toxicity secondary to therapeutic
regimens that are used to treat these patients [1, 2, 3, 4].
Management of refractory disease requires careful bal-
ancing of the side effects associated with therapy with
the risks associated with persistent NS. Patients with
complicated courses of NS often demonstrate highly
variable responses to therapy with immunosuppressive
agents, including oral and intravenous corticosteroids,
cyclophosphamide, and cyclosporin-A (Cs-A) [1, 2, 3, 
4, 5].
Our center has used Cs-A in patients with SRNS to
achieve remission. Many of our SRNS patients who have
responded to treatment with Cs-A have been difficult to
wean off Cs-A without relapse. To treat these Cs-A-de-
pendent patients, as well as patients with FR-SDNS, our
center has utilized a 12-week course of cyclophospha-
mide (168 mg/kg per course) according to International
Study of Kidney Disease in Children (ISKDC) guide-
lines [5] in an attempt to achieve prolonged Cs-A and
steroid-free remission, with limited success (unpublished
observations).
In patients that continue to have persistent FR-SDNS
or Cs-A-dependent SRNS after receiving a 12-week
course of cyclophosphamide, the treatment options may
include high-dose pulse steroids or initiation/continua-
tion of Cs-A. Both of these therapies involve significant
risk for side effects. Although Cs-A is effective in treat-
ing such difficult cases of NS, its use can be complicated
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by long-term renal toxicity, as well as persistent relapses
after withdrawal [1, 2, 3, 4].
Mycophenolate mofetil (MMF) is an immunosuppres-
sive agent that has been successfully used for the preven-
tion of acute rejection of renal allografts [6, 7]. More re-
cently, MMF has been reported to be effective in reduc-
ing proteinuria in some patients with resistant and idio-
pathic membranous nephropathy [8], adult onset im-
mune-mediated glomerular disease [9], and, in a case re-
port, in inducing remission of relapsing NS [10]. In an
effort to reduce the potential side effects associated with
the treatment of difficult-to-manage post-cyclophospha-
mide SRNS and FR-SDNS, we have used MMF as a
third-line agent.
Patients and methods
We retrospectively analyzed 14 patients with either SRNS or FR-
SDNS who had been treated with MMF at our center over the past
4 years. SRNS was defined as failure to respond with either com-
plete or partial remission after an initial course of at least
4–8 weeks of daily steroids (prednisone 2 mg/kg per day). FR-
SDNS was defined as complete remission [urinary protein excre-
tion of <4 mg/h per m2 or reagent strip (Albustix) with negative or
trace protein for at least 3 consecutive days] after an initial 4- to 
8-week course of daily steroids, but relapse (urinary protein excre-
tion of >40 mg/h per m2 or reagent strip of 2+ or more protein for
3 consecutive days, having previously been in remission) immedi-
ately after weaning to alternate-day steroid dosing, and demonstra-
tion of significant steroid toxicity. Patients were considered to
have frequently relapsing NS if they had documented two or more
relapses within a 6-month period of initial response, or four or
more relapses within any 12-month period.
All renal biopsies were performed percutaneously under ultra-
sound guidance by using a 16- or 18-gauge biopsy needle (Bard,
Covington, Ga., USA). Biopsies were examined by light micros-
copy (hematoxylin and eosin and periodic acid-Schiff stains), im-
munofluorescence microscopy (IF), and electron microscopy
(EM). Specimens were examined by renal pathologists. Diagnoses
were made using standard histological classifications. Minimal
change nephrotic syndrome was defined as the absence of abnor-
malities or mild histological changes noted on light and IF micros-
copy, with merely diffuse foot-process fusion on EM. IgM neph-
ropathy was classified as diffuse mesangial proliferation/hypercel-
lularity without segmental glomerular sclerosis noted on light mi-
croscopy, with mesangial IgM deposition on IF, and foot-process
fusion and mesangial immune deposits observed with EM. Focal
segmental glomerular sclerosis was identified by the presence of
focal glomerular abnormalities with segmental areas of sclerosis.
IF was positive for IgM and C3 deposition, and EM demonstrated
mesangial immune deposits and foot-process fusion.
MMF was offered as a treatment option for Cs-A- and/or ste-
roid-dependent patients that had failed previous attempts at with-
drawal of Cs-A or steroids. Prior to initiating treatment, signed in-
formed consent for MMF treatment was obtained from the patient
and/or parents. Families were informed of the potential risks asso-
ciated with MMF therapy, and offered the option of alternative
management with Cs-A or continuation of steroids alone. Data
collection for this retrospective study was approved by the Institu-
tional Review Board for Human Subject Research (IRBMED).
MMF was begun at an initial dose of 800 mg/m2 per day. All
patients were administered H2 blockers at initiation of therapy in
an attempt to prevent gastrointestinal side effects. White blood
cell count (WBC) was measured 2 weeks after the initiation of
therapy and then at monthly intervals. Dosage of MMF was titrat-
ed up to 1,200 mg/m2 per day as WBC allowed (target WBC
>4×106/mm3). Patients were administered MMF for approximately
8–12 weeks before attempting to wean steroids or Cs-A over the
subsequent 6–12 months.
Numerical data were analyzed using paired t-test (two-tailed)
using Statview (Abacus Concepts, Berkeley, Calif., USA). Data
are expressed as mean±standard error (SE), with P value <0.05
considered significant.
Results
Patient characteristics are outlined in Table 1. The 
patients were diagnosed with NS at an average age 
of 33.5 months (range 12–62 months). All patients 
carried the diagnosis of either CsA-dependent SRNS or 
FR-SDNS (5 patients were diagnosed with SRNS and 9
with FR-SDNS). Each patient had been previously treat-
ed with at least one 12-week course of oral cyclophos-
phamide (dosage 168 mg/kg per course)—3 patients had
received more than one 12-week course. Seven patients
received cyclophosphamide while simultaneously treated
with Cs-A. The remaining patients received cyclophos-
phamide prior to initiation of treatment with Cs-A.
On initial biopsy, 5 patients were noted to have pa-
thology consistent with MCNS, while 9 carried the diag-
nosis of IgM nephropathy. Two patients (1 initially diag-
nosed with MCNS and 1 with IgM nephropathy) had fol-
low-up biopsies consistent with FSGS.
Ten of the patients had been treated with Cs-A 
(Sandimmune) for an average of 77 months (range
48–113 months) and had failed prior attempts to wean
Cs-A. These patients were offered MMF in an attempt to
allow weaning of Cs-A. Cyclosporine levels prior to ini-
tiation of therapy with MMF had been maintained at a
whole-blood level (high-performance liquid chromatog-
raphy) of approximately 80–100 ng/ml. Of the 10 pa-
tients on Cs-A, 4 had surveillance biopsies consistent
with Cs-A toxicity. In total, 8 of the 10 patients had in-
terstitial fibrosis attributed to primary disease or evi-
dence of Cs-A toxicity on biopsy prior to initiation of
MMF. The remaining 4 children with FR-SDNS that had
never received Cs-A were started on MMF after repeated
relapses following a 12-week course of cyclophospha-
mide in an attempt to avoid the use of prolonged steroids
or adding Cs-A therapy.
The average age of patients at time of initiation 
of therapy with MMF was 119 months (range 41–
190 months). The number of relapses in the 12 months
prior to initiation of MMF therapy was compared with
the number of relapses during the 12 months after 
starting MMF. The mean number of relapses in the
12 months preceding MMF therapy was 2.85 (±0.4),
compared with 1.07 (±0.3) in the 12 months following
initiation of MMF treatment (±standard error, P<0.01,
paired t-test).
Of the 10 patients that were on Cs-A, 5 were weaned
to MMF monotherapy. Patients 1, 2, 3, 5, and 10 were
weaned off Cs-A and steroids by 1–2 years of follow-up.
Two patients (1 and 10) have remained relapse free. Two
patients (2 and 3) had one relapse each and both re-






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































restart Cs-A therapy. In addition, 1 patient (no. 5) was
weaned off Cs-A and MMF, and has remained in remis-
sion off all therapy for 10 months.
There was a reduction in the dose of Cs-A required to
maintain remission in patients 8 and 9. Both were com-
pletely weaned off steroids. While tapering Cs-A, patient
no. 8 had a relapse treated with a small increase in Cs-A
dose, without addition of steroids. Once in remission,
Cs-A was weaned again to 25% of the original (pre
MMF) dose, with levels maintained at 40–50 ng/ml,
while remaining in remission. Patients 4 and 7, with in-
tractable SRNS, continued to relapse repeatedly on
MMF and Cs-A.
The subgroup of patients with FR-SDNS not treated
with Cs-A (patients 11–14) appeared to have a slight
overall reduction in the number of relapses while on
MMF therapy. However, the difference between the
number of relapses pre MMF and post initiation of MMF
therapy in this subgroup did not reach statistical signifi-
cance (pre MMF 4.25±0.63 versus post MMF 1.75±0.48,
P=0.06). Nonetheless, there was 1 patient (no. 12) that
we were able to wean off steroids and eventually off
MMF as well.
Patients 6 and 11 had difficulties tolerating MMF, and
experienced significant side effects while on MMF ther-
apy. Patient 6 experienced considerable abdominal dis-
comfort, diarrhea, malaise, and splenomegaly. MMF was
therefore discontinued after only 3 months of therapy.
This patient remains on Cs-A and steroids, and continues
to relapse approximately once a year. Patient 11 had a
relatively high rate of relapse even with MMF treatment
(3 relapses in 12 months), was off MMF therapy for 
approximately 6 weeks because of gastrointestinal side
effects, and relapsed during that time (this relapse was
not included in the analysis). MMF therapy was then re-
sumed, and the patent was able to continue on treatment
for the subsequent 12 months. Overall, with close moni-
toring of WBC and titration of MMF dosages according-
ly, no leukopenia (WBC <2×106/mm3) was noted in any
of our patients.
Discussion
Management of persistent NS after treatment with oral
cyclophosphamide presents a therapeutic quandary in
FR-SDNS and Cs-A-dependent SRNS patients. Treat-
ment options for such refractory disease include Cs-A
and high-dose pulse steroids, both of which have signifi-
cant side effects. Our center has offered MMF to these
patients with FR-SDNS and Cs-A-dependent SRNS in
an effort to reduce the number of relapses and limit the
extent of steroid and Cs-A exposure.
In this retrospective study, there were fewer relapses
during the 12 months following initiation of therapy with
MMF, than in the 12 months preceding treatment with
MMF. Overall, there is a trend toward fewer relapses af-
ter initiation of MMF that reaches statistical signifi-
cance. Many of the relapses that had occurred during
MMF treatment resulted when steroids or Cs-A were be-
ing weaned. However, when relapses occurred while on
MMF therapy, patients appeared to respond to shorter
courses of steroids and/or slight increases in Cs-A doses
in order to achieve remission, than they had required pri-
or to starting MMF (unpublished observations). Because
this is a retrospective review, we were unable to calcu-
late the precise differences in the average steroid dose
per patient year. Six of our patients have been steroid
and Cs-A free for several months and are currently being
weaned from their MMF—2 patients have already been
completely weaned off MMF, and have remained relapse
free. Whether there will be any long-lasting benefit of
MMF treatment remains to be determined.
Despite appropriate dosing and close monitoring of
laboratory studies, some side effects associated with
MMF were noted. The presence of gastrointestinal side
effects, despite the use of prophylactic H2 blockers, 
required reduction of dosage and discontinuation of
treatment for short periods in 2 of our patients. How-
ever, no significant leukopenia or infectious complica-
tions were observed in any of the patients included in
this study.
In this small, single-center, uncontrolled experience,
MMF therapy in patients with FR-SDNS and Cs-A-
dependent SRNS appears to be effective in reducing ste-
roid and Cs-A exposure, and may represent a potentially
less toxic alternative to Cs-A. MMF therapy also ap-
pears to help maintain patients in remission and has
demonstrated a significant decrease in the overall 
frequency and severity of relapses after initiation of
therapy.
Our experience suggests that MMF may be a useful
adjunctive agent in the treatment of difficult cases of
NS. It is important to note that all of our patients were
responsive to either steroids or Cs-A. Thus, our experi-
ence does not apply to treatment of patients with com-
pletely resistant NS. Controlled, prospective trials are
needed to confirm these findings and better define the
optimal duration of MMF therapy. In addition, further
studies are warranted to determine the potential efficacy
and side effects of long-term MMF therapy in this set-
ting.
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